Related Experiment Video
Updated: Mar 24, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
[Treatment of recurrent glioblastoma with single-agent bevacizumab]
Dániel Sinkó1, Csaba Nemeskéri1
1Fővárosi Onkoradiológiai Központ, Uzsoki Utcai Kórház, Semmelweis Egyetem Oktató Kórháza Budapest, Uzsoki u. 29., 1149.
Introduction:
The prognosis of patients with recurrent glioblastoma is poor, as the median survival does not exceed 6 months.
Aim:
The aim of this study was to evaluate the efficacy of bevacizumab monotherapy in patients with recurrent glioblastoma multiforme.
Method:
From April, 2012 to June, 2015, 40 patients with recurrent glioblastoma multiforme were treated with bevacizumab in a dose of 10 mg/kg every 2 weeks.
Results:
The average progression-free survival was 6.4 months (2-22 months), and the 6-month progression-free survival was 42.5%. The six-month overall survival was 82.5%, which corresponds to those published in the literature.
Conclusions:
Bevacizumab monotherapy improves progression-free survival in patients with recurrent glioblastoma multiforme.
Related Concept Videos
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers